Back to top

cell-therapy: Archive

Zacks Equity Research

Agilent (A) Boosts DGG Offerings With PD-L1 IHC 22C3 Approval

Agilent (A) receives FDA approval for its PD-L1 IHC 22C3 diagnostic tool, benefiting PD1/PDL1 cancer patients.

CRMPositive Net Change BMINegative Net Change ANegative Net Change ANETNegative Net Change

Zacks Equity Research

Nkarta (NKTX) Rallies 112% as FDA Clears IND for Lupus Drug

Nkarta (NKTX) rallies 112% on FDA nod to begin the clinical development of its investigational candidate, NKX019, for the treatment of lupus nephritis.

DVAXPositive Net Change ACETNegative Net Change ANIXPositive Net Change NKTXNegative Net Change